|
Vivelle-Dot®
(estradiol transdermal
system)

Worlds Smallest
Estrogen Patch
Most Dispensed Estrogen Patch in U.S.
In May ,
1999, Vivelle-Dot® (estradiol transdermal system),
the worlds smallest transdermal estrogen delivery system, was launched
in the U.S. This state-of-the-art patch was approved for the treatment
of the symptoms of menopause. Vivelle-Dot® is marketed and sold by Novogyne
Pharmaceuticals, a womens health products company jointly owned
by Noven and Novartis.
Vivelle-Dot® is indicated for the treatment of the symptoms of menopause, and the
prevention of postmenopausal osteoporosis. Vivelle-Dot® is
available in five dosage strengths (.025, .0375, .05, .075 and .10
mg/day) with the .025 dosage strength
indicated for the prevention of postmenopausal osteoporosis only.
These
five strengths provide prescribing physicians with broad dosing flexibility.
In the most commonly prescribed dosage strength (.05 mg/day), Vivelle-Dot® is about the size and thickness of a postage stamp. By area, it is about
one-third the size of Climara® (Berlex) and about one-quarter
the size of Estraderm® (Novartis). The .025 mg/day dosage
strength is the size of a dime (2.5cm2).
Novens market
research indicated that patients would prefer a smaller, less conspicuous
estrogen patch that is well-suited to an active lifestyle. In response,
Noven engineered a new generation system by far the smallest
available
that is thin, translucent and extremely adherent, permitting
patients to exercise, shower and swim without the need to change patches.
Vivelle-Dot® utilizes
Novens
proprietary DOT Matrix® adhesive technology
and delivers estradiol through the skin and into the bloodstream. The
technologies incorporated into Vivelle-Dot® are the
subject of a number of U.S. patents.
For more information,
please visit www.vivelledot.com

For patient and physician
inquiries regarding
Vivelle-Dot®, please contact:
Customer Interaction
Center
Novartis Pharmaceuticals Corporation
One Health Plaza
Building 122
East Hanover, New Jersey 07936
Phone: 888-669-6682
Fax: 973-781-3115
Click
here for E-mail Contact
WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD
KNOW ABOUT VIVELLE-DOT (AN ESTROGEN HORMONE)?
Estrogens increase the chances of getting
cancer of the uterus (womb). Report any unusual vaginal bleeding right
away while you are taking estrogens. Vaginal bleeding after menopause
may be a warning sign of cancer of the uterus (womb).
Do not use estrogens
with or without progestins to prevent heart disease, heart attacks, or
strokes. Using estrogens with progestins may increase your risk of dementia
(decline in memory and thinking skills).
Vivelle-Dot should not be used
if you have unusual vaginal bleeding; currently have or have had certain
cancers, including cancer of the breast or uterus; had a stroke or heart
attack in the recent past (for example, in the past year); currently
have or have had blood clots; currently have or have had liver problems;
or think you may be, or know that you are, pregnant.
The most common
side effects that may occur with Vivelle-Dot are headache, breast tenderness,
and back pain.
Vivelle-Dot is used after menopause to: reduce moderate
to severe hot flashes; treat moderate to severe dryness, itching and
burning in or around the vagina; help reduce your chances of getting
osteoporosis (thin weak bones); and treat certain conditions in which
a young woman’s ovaries do not produce enough estrogens naturally.
Vivelle-Dot 0.025 mg/day is only used to prevent osteoporosis from menopause.
If you use Vivelle-Dot only to treat your dryness, itching, and burning
in and around your vagina or if you use Vivelle-Dot only to prevent osteoporosis
from menopause, talk with your healthcare professional about whether
a different treatment or medicine without estrogens might be better for
you.
You and your healthcare professional should talk regularly about
whether you still need treatment with Vivelle-Dot. The information contained
within this Web site is appropriate for U.S. residents only. A visit
to this site should not replace a visit to your doctor.
Available by
prescription only.
Copyright © 2008 Noven
Pharmaceuticals, Inc. All rights reserved.
|